Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex in Peripheral Neuropathic Pain with Allodynia
NCT00711880Phase 3
Key facts
- Status
- Completed
- Start
- May 2002
- Primary completion
- Mar 2004
- Countries
- 1
- Sponsor
- Jazz Pharmaceuticals plc
- Modality
- Small Molecules
- Drugs
- cannabidiol
- Conditions
- Peripheral neuropathic pain
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in Peripheral neuropathic pain, sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Numerical Rating Scale at Day 42. Started May 2002; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults with chronic peripheral neuropathic pain (6+ months) and mechanical allodynia, on a stable dose of analgesics, with a baseline pain score of 4 or higher.
04
Endpoints
Primary
Numerical Rating Scale
Secondary
Neuropathic Pain Scale
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT00711880.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00711880.